β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer’s Disease
Hans Hilpert(Roche (Switzerland)), Robert Narquizian(Roche (Switzerland)), Roland Humm(Roche (Switzerland)), Wolfgang Guba(Roche (Switzerland)), Thomas J. Woltering(Roche (Switzerland)), Holger Fischer(Roche (Switzerland)), Daniela Krummenacher(Roche (Switzerland)), Mark Rogers‐Evans(Roche (Switzerland)), Emmanuel Pinard(Roche (Switzerland)), Christian Schnider(Roche (Switzerland)), Pascale David‐Pierson(Roche (Switzerland)), Alessandra Polara(University of Cambridge), Wolfgang Wostl(Roche (Switzerland)), Harald Mauser(Roche (Switzerland)), Helmut Jacobsen(Roche (Switzerland)), A. Kuglstatter(Roche (Switzerland)), Alessandra Bergadano(Roche (Switzerland)), Remo Hochstrasser(Roche (Switzerland)), Laurence Ozmen(Roche (Switzerland)), Thorsten Muser(Roche (Switzerland)), David W. Banner(Roche (Switzerland)), A. Mayweg(Roche (Switzerland))
Cited by 138
Related Papers
Fluorine in Medicinal Chemistry
|ChemBioChem|2004|1.5k
Oxetanes as Versatile Elements in Drug Discovery and Synthesis
|Angewandte Chemie International Edition|2010|435
Oxetanes in Drug Discovery: Structural and Synthetic Insights
|Journal of Medicinal Chemistry|2010|405
Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP–TEAD Protein–Protein Interaction
|ACS Medicinal Chemistry Letters|2014|174